Gemtuzumab Ozogamicin

Antibody–drug conjugate

Approvedregulatory verdict

Evidence outlook

Approved: Acute Myeloid Leukemia

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (3)
US
  • Relapsed or Refractory CD33-positive AML MYLOTARG is indicated for the treatment of relapsed or refractory CD33-positive acute myeloid leukemia in adults and pediatric patients 2 years and older.
Product first approved 2017Outside this platform's coverageFDA label
EU
  • Combination therapy with daunorubicin and cytarabine for previously untreated de novo CD33-positive AML, age 15 and above, excluding APL
Product first approved 2018EMA
JP
  • Acute myeloid leukemia (relapsed/refractory CD33-positive; applicant Wyeth Japan, now Pfizer)
Product first approved 2005biospace.com

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (15)
Acute Myeloid Leukemia
NCT02724163 · University of Birmingham
2016-04 – 2032-12 · Acute Myeloid Leukaemia
What this study did
NCT05183035 · PedAL BCU, LLC
2022-10-01 – 2031-04 · Acute Myeloid Leukemia
What this study did
NCT04293562 · Children's Oncology Group
2020-07-21 – 2029-06-30 · Acute Myeloid Leukemia
What this study did
NCT04168502 · Gruppo Italiano Malattie EMatologiche dell'Adulto
2020-09-24 – 2027-04 · Acute Myeloid Leukemia
What this study did
NCT04093505 · University Hospital Heidelberg
2021-04-01 – 2022-06-23 · Acute Myeloid Leukemia
What this study did
NCT00049517 · Eastern Cooperative Oncology Group
2002-12-19 – 2019-12 · Leukemia
What this study did
NCT00860639 · Nantes University Hospital
2007-10 – 2016-09-26 · Acute Myeloid Leukemia
What this study did
NCT00121303 · Stichting Hemato-Oncologie voor Volwassenen Nederland
2005-01 – 2016-06 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00085709 · SWOG Cancer Research Network
2004-07 – 2014-08 · Leukemia
What this study did
NCT00476541 · University of Aarhus
2004-01 – 2012-01 · Acute Myeloid Leukemia
What this study did
NCT00962767 · Wyeth is now a wholly owned subsidiary of Pfizer
2002-05 – 2007-12 · Leukemia, Myelocytic, Acute
What this study did
Phase 2/3 (6)
Acute Myeloid Leukemia
NCT02272478 · Cardiff University
2014-10-30 – 2022-02 · Acute Myeloid Leukaemia, Myelodysplastic Syndrome
What this study did
NCT00909168 · University Hospital, Udine, Italy
2008-03 – 2013-03 · Acute Myeloid Leukemia
What this study did
NCT00454480 · The University of New South Wales
2006-08 – 2012-08 · Leukemia, Myelodysplastic Syndromes
What this study did
Phase 2 (43)
Acute Myeloid Leukemia
NCT00801489 · M.D. Anderson Cancer Center
2007-04-04 – 2028-10-11 · Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1, de Novo Myelodysplastic Syndrome, High Risk Myelodysplastic Syndrome, Inv(16), Myelodysplastic Syndrome With Excess Blasts, t(16;16), t(8;21), Untreated Adult Acute Myeloid Leukemia
What this study did
NCT05599360 · Shaare Zedek Medical Center
2022-08-07 – 2028-09-07 · Leukemia, Myeloid, Acute
What this study did
NCT05199051 · Centre Antoine Lacassagne
2023-06-03 – 2028-07-10 · AML, Leukaemia (Acute Myeloid)
What this study did
NCT04050280 · University of Maryland, Baltimore
2019-11-01 – 2028-02 · Acute Myeloid Leukemia, Adult, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, Relapsed, Adult
What this study did
NCT03589729 · M.D. Anderson Cancer Center
2018-09-19 – 2027-12-31 · Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts 10 Percent or More of Bone Marrow Nucleated Cells, High Risk Myelodysplastic Syndrome, Myeloid Sarcoma, Myeloproliferative Neoplasm, Philadelphia Chromosome Positive
What this study did
NCT01409161 · M.D. Anderson Cancer Center
2011-10-05 – 2027-12-18 · Acute Promyelocytic Leukemia With PML-RARA
What this study did
NCT04793919 · Associazione Italiana Ematologia Oncologia Pediatrica
2019-10-09 – 2027-10-10 · Acute Promyelocytic Leukemia
What this study did
NCT00658814 · National Cancer Institute (NCI)
2008-12-01 – 2027-03-31 · Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22.1); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p21.3;q23.3); MLLT3-KMT2A, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
NCT03737955 · University of Washington
2018-11-30 – 2026-12-31 · Acute Myeloid Leukemia
What this study did
NCT03672539 · M.D. Anderson Cancer Center
2018-11-07 – 2026-07-17 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia, High Risk Myelodysplastic Syndrome, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT02221310 · New York Medical College
2011-12-07 – 2023-04-04 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT02117297 · New York Medical College
2012-01-12 – 2023-03-30 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT04173585 · University Hospital Heidelberg
2019-10-22 – 2023-03-24 · Acute Myeloid Leukemia
What this study did
NCT04326439 · Emory University
2020-01-24 – 2022-03-15 · Acute Myeloid Leukemia, AML, Childhood
What this study did
NCT00551460 · SWOG Cancer Research Network
2007-11-15 – 2018-02-05 · Leukemia
What this study did
NCT01698879 · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
2009-10 – 2016-09-26 · Novo Acute Myeloid Leukemia
What this study did
NCT00413166 · M.D. Anderson Cancer Center
2006-12 – 2016-02 · Acute Promyelocytic Leukemia
What this study did
NCT01548911 · Wake Forest University Health Sciences
2012-05 – 2013-09 · Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Promyelocytic Leukemia (M3), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT00968071 · M.D. Anderson Cancer Center
2008-02 – 2012-08 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT00882102 · M.D. Anderson Cancer Center
2009-04 – 2012-08 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome
What this study did
NCT01723657 · Grupo Cooperativo de Estudio y Tratamiento de las Leucemias Agudas y Mielodisplasias
2003-10 – 2012-03 · Leukemia, Myelocytic, Acute
What this study did
NCT00049179 · SWOG Cancer Research Network
2003-04 – 2010-10 · Leukemia
What this study did
NCT00673153 · Fred Hutchinson Cancer Center
2008-03 – 2010-08 · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
What this study did
NCT01039363 · Samsung Medical Center
— · Acute Myeloid Leukemia
What this study did
NCT00143975 · University of Ulm
2004-06 – 2009-06 · Leukemia, Myeloid, Acute
What this study did
NCT00195000 · Weill Medical College of Cornell University
2003-05 – 2008-02 · Acute Myeloid Leukemia, Myelodysplastic Syndrome
What this study did
NCT00005962 · Eastern Cooperative Oncology Group
2000-10-04 – 2007-06 · Leukemia
What this study did
NCT00077116 · European Organisation for Research and Treatment of Cancer - EORTC
2003-11 – 2006-11 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00017589 · Genta Incorporated
2000-12 – 2006-05 · Leukemia
What this study did
NCT00089050 · Fred Hutchinson Cancer Center
2004-05 – 2006-03 · Leukemia
What this study did
NCT00006265 · Alliance for Clinical Trials in Oncology
2001-03 – 2005-05 · Leukemia
What this study did
NCT00044733 · Wyeth is now a wholly owned subsidiary of Pfizer
2000-03 – 2004-09 · Acute Myelogenous Leukemia
What this study did
NCT00037583 · Wyeth is now a wholly owned subsidiary of Pfizer
est. completion 2003-09 · Acute Myeloid Leukemia
What this study did
NCT00037596 · Wyeth is now a wholly owned subsidiary of Pfizer
2000-08 – 2003-04 · Acute Myeloid Leukemia
What this study did
NCT00003131 · Pfizer
1997-02 – 2002-02 · Leukemia
What this study did
NCT00006122 · European Organisation for Research and Treatment of Cancer - EORTC
2000-06 – 2002-01 · Leukemia
What this study did
NCT00003673 · Pfizer
1998-03 – 1999-03 · Leukemia
What this study did
Other / comorbidity
NCT00022321 · Jonsson Comprehensive Cancer Center
started 2001-09 · Myelodysplastic Syndromes
What this study did
NCT00274781 · The Cleveland Clinic
2004-02 – 2010-11 · Leukemia, Myelodysplastic Syndromes
What this study did
Phase 1/2 (11)
Acute Myeloid Leukemia
NCT04385290 · Technische Universität Dresden
2020-09-04 – 2028-04 · Acute Myeloid Leukemia
What this study did
NCT04849910 · Vor Biopharma
2021-12-16 – 2025-05-28 · Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
What this study did
NCT03374332 · Brown University
2019-12-31 – 2025-03-31 · Acute Myeloid Leukemia
What this study did
NCT03390296 · M.D. Anderson Cancer Center
2017-12-27 – 2022-02-04 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03531918 · Fred Hutchinson Cancer Center
2018-09-14 – 2021-11-01 · Acute Myeloid Leukemia
What this study did
NCT00766116 · University of California, San Diego
2005-07 – 2014-09-26 · Acute Myeloid Leukemia
What this study did
NCT00895934 · National Cancer Institute (NCI)
2009-05 – 2013-09 · Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
What this study did
NCT02182596 · Acute Leukemia French Association
2006-06 – 2011-01 · Acute Myeloid Leukemia
What this study did
NCT00233909 · Kanisa Pharmaceuticals
2005-10 – 2008-03 · Leukemia, Myeloid
What this study did
NCT00460447 · University Hospital Carl Gustav Carus
started 2004-10 · Acute Myeloid Leukemia, Allogeneic Transplantation
What this study did
NCT00038831 · M.D. Anderson Cancer Center
2001-05 – 2006-10 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia
What this study did
Phase 1 (17)
Acute Myeloid Leukemia
NCT06448013 · M.D. Anderson Cancer Center
2025-03-07 – 2030-12-31 · Acute Myeloid Leukemia
What this study did
NCT05662904 · German Cancer Research Center
2028-01 – 2030-01 · Relapsed/Refractory Acute Myeloid Leukemia (AML)
What this study did
NCT05558124 · H. Lee Moffitt Cancer Center and Research Institute
2023-02-16 – 2027-04 · Acute Myeloid Leukemia
What this study did
NCT03568994 · Baylor College of Medicine
2018-07-10 – 2025-09-20 · Acute Myeloid Leukemia
What this study did
NCT05716009 · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
2023-11-20 – 2025-07-16 · Acute Myeloid Leukemia
What this study did
NCT04915612 · M.D. Anderson Cancer Center
2021-05-21 – 2025-01-30 · Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
What this study did
NCT04207190 · Roswell Park Cancer Institute
2020-10-23 – 2024-06-29 · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
What this study did
NCT03904251 · Jonsson Comprehensive Cancer Center
2019-07-18 – 2023-10-25 · Acute Myelogenous Leukemia
What this study did
NCT03878927 · Weill Medical College of Cornell University
2019-08-23 – 2022-09-01 · Acute Myeloid Leukemia
What this study did
NCT03848754 · Medical College of Wisconsin
2019-05-24 – 2021-05-05 · Relapsed Adult AML
What this study did
NCT01020539 · Columbia University
2002-09-11 – 2020-12 · Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Juvenile Myelomonocytic Leukemia
What this study did
NCT00577694 · UNC Lineberger Comprehensive Cancer Center
2007-11 – 2015-08 · Leukemia
What this study did
NCT00669890 · New York Medical College
2004-05 – 2013-12 · Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome
What this study did
NCT00028899 · Children's Oncology Group
2002-07 – 2012-03 · Leukemia, Myelodysplastic Syndromes
What this study did
NCT00660036 · University of Pittsburgh
2008-09 – 2011-04 · Acute Myeloid Leukemia
What this study did
Phase 4 (3)
Acute Myeloid Leukemia
NCT03727750 · Pfizer
2019-07-03 – 2021-04-27 · ECG, Pharmacokinetics, Safety
What this study did
Other / comorbidity
NCT00304447 · Wyeth is now a wholly owned subsidiary of Pfizer
2002-04 – 2004-01 · Leukemia, Myelocytic, Acute, Infusions, Intravenous
What this study did
Used as active comparator (3)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 2 (3)
Acute Myeloid Leukemia
NCT05904106 · Technische Universität Dresden
2024-04-07 – 2030-09 · Acute Myeloid Leukemia
What this study did
NCT05564390 · National Cancer Institute (NCI)
2024-06-18 – 2029-05-15 · Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic/Myeloproliferative Neoplasm, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia, Myelodysplasia-Related, Myelodysplastic Syndrome
What this study did
NCT00798213 · Merck Sharp & Dohme LLC
2009-01 – 2010-04 · Leukemia, Myeloid, Acute, Lymphoblastic Leukemia, Acute
What this study did
Appears in other studies (2)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
Acute Myeloid Leukemia
NCT00136084 · St. Jude Children's Research Hospital
2002-08 – 2012-06 · Leukemia, Myelocytic, Acute
What this study did
Phase 2 (1)
Acute Myeloid Leukemia
NCT05955261 · St. Jude Children's Research Hospital
2023-07-25 – 2034-03 · Acute Myeloid Leukemia
What this study did

Competitive landscape

4 other tracked programmes target this mechanism, none of them ahead of this one.

This drug's own stage for Acute Myeloid Leukemia: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Gemtuzumab Ozogamicin: this drugApprovedAntibody–drug conjugateCD33Partial signal
NCT00893399: Short-term event-free survival at 6-month follow-up: 53% standard vs 58% gemtuzumab ozogamicin (HR 0·83; p=0·10); 2-year overall survival: 69% vs 73% (0·90; p=0·43) missed
NCT00372593: Two primaries at 3 years: event-free survival 53.1% with gemtuzumab ozogamicin plus chemotherapy vs 46.9% with chemotherapy alone, HR 0.83 (95% CI 0.70 to 0.99), P = .04 (met); overall survival 69.4% vs 65.4%, HR 0.91 (95% CI 0.74 to 1.13), P = .39 (missed); 1,022 evaluable patients.
Azacitidine (Onureg)ApprovedSmall moleculeDNMT1 (DNA methyltransferase 1)Weak signal
NCT01757535: QUAZAR AML-001 (n=472), primary endpoint overall survival: median 24.7 months (95% CI 18.7 to 30.5) with oral azacitidine vs 14.8 months (95% CI 11.7 to 17.6) with placebo; HR 0.69 (95% CI 0.55 to 0.86), stratified log-rank p=0.0009 (CT.gov posted results).
Decitabine / Cedazuridine (Inqovi)ApprovedSmall moleculeDecitabine/cedazuridine fixed combination (DNMT + CDA inhibition)Partial signalFeatured results are non-efficacy only in this race
Enasidenib (Idhifa)ApprovedSmall moleculeIDH2Partial signal
NCT02577406: Overall Survival (OS) (From randomization to death due to any cause (up to approximately 49 months)): AG-221 6.5 Months (95% CI 5.5 to 9.5) missed
GilteritinibApprovedSmall moleculeFLT3Partial signal
NCT02752035: Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) missed
GlasdegibApprovedSmall moleculeHedgehog Pathway InhibitorPartial signalNo reviewed efficacy summary in this indication
Ivosidenib (Tibsovo)ApprovedSmall moleculeMutant IDH1Reliable signal
NCT03173248: Event-free survival HR 0.33 (95% CI 0.16 to 0.69), one-sided stratified log-rank p = 0.0011 (registry analysis)
Midostaurin (Rydapt)ApprovedSmall moleculeFLT3;KIT;PKC;PDGFRWeak signal
NCT03512197: Event Free Survival (EFS) (From date of Randomization up to approx. 30 months): Midostaurin + Chemotherapy 5.98 Months (95% CI 2.33 to 8.97) vs Placebo + Chemotherapy 5.88 Months (95% CI 3.65 to 7.52) missed
NCT00651261: Overall survival, chemotherapy + midostaurin vs chemotherapy + placebo: median 74.7 vs 25.6 months, hazard ratio 0.78 (95% CI 0.63 to 0.96), one-sided p=0.009 (n=360 and 357) (CT.gov posted results).
OlutasidenibApprovedSmall moleculeMutant IDH1Weak signalFeatured results are safety only in this race
Orca-T (TREGZI)ApprovedCell therapyAllogeneic engineered T-cell immunotherapyPartial signal
NCT05316701: Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC) (Day 0 through 730 days after transplantation): Orca-T 78% (95% CI 65 to 86.6) vs Standard of Care 38.4% (95% CI 26.2 to 50.5)
QuizartinibApprovedSmall moleculeFLT3Reliable signal
NCT02668653: Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2)
RevumenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
Sargramostim (Leukine)ApprovedProtein / enzyme therapeuticGM-CSF receptornot yet gradedNo reviewed efficacy summary in this indication
Tretinoin (Vesanoid)
ApprovedUS marketing discontinued
Small moleculeRARA (retinoic acid receptor alpha); degrades the PML-RARA fusion oncoprotein in APLnot yet graded
NCT00003934: Complete remission (response rate): 90% in each arm. Event-free survival at 3 years (a co-registered primary endpoint): 80% with arsenic trioxide (As2O3) consolidation vs 63% with standard consolidation alone (P<.0001). phase 3 result · pivotal pending
VenetoclaxApprovedSmall moleculeBCL-2Reliable signal
NCT03069352: Overall Survival (OS) (From randomization until the primary analysis cut-off date of February 15 2019; the median follow-up time was 12.0 months (range: 0.2-17.0) in the placebo arm and 12.0 months (range: 0.1-17.6) in the venetoclax arm.): Venetoclax + Low Dose Cytarabine (LDAC) 7.2 months (95% CI 5.6 to 10.1) | Placebo + Low Dose Cytarabine (LDAC) 4.1 months (95% CI 3.1 to 8.8) missed
VyxeosApprovedSmall moleculeDNA synthesis (cytarabine, antimetabolite) / Topoisomerase IIPartial signal
NCT01696084: Overall survival, Vyxeos (CPX-351) vs 7+3 in patients 60 to 75 years with newly diagnosed t-AML or AML-MRC: median 9.6 months (95% CI 6.6 to 11.9) vs 5.9 months (95% CI 5.0 to 7.8); HR 0.69 (95% CI 0.52 to 0.90), two-sided p=0.005. n=153 vs 156 (FDA label, Study 1).
ZiftomenibApprovedSmall moleculeMeninWeak signalNo reviewed efficacy summary in this indication
131I-ApamistamabPhase 3Monoclonal antibodyCD45Partial signal
NCT02665065: SIERRA (NCT02665065), primary endpoint durable complete remission (dCR) at 6 months: Iomab-B 22% (13/59) vs control 0%; p<0.0001
Arsenic Trioxide (QTX-2101)Phase 3Small moleculePML-RARA fusion oncoproteinnot yet gradedNo reviewed efficacy summary in this indication
Arsenic Trioxide (SDK001)Phase 3Small moleculePML-RARA fusion oncoproteinPartial signalNo reviewed efficacy summary in this indication
AzacitidinePhase 3Small moleculeDNMT1 (DNA methyltransferase 1)Partial signal
NCT00887068: Relapse-free survival: median 2.07 years with azacitidine maintenance vs 1.28 years with observation (P=.43); multivariate hazard ratio 0.73 (95% CI 0.49 to 1.1; P=.14) (Oran et al., Blood Adv 2020). missed
BleximenibPhase 3Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
Clifutinib BesylatePhase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
CrenolanibPhase 3Small moleculeFLT3 (including D835/ITD mutants), also PDGFR-alpha/betaReliable signal
NCT03250338: EFS: 3.4 vs. 0.0 months crenolanib plus chemotherapy vs chemotherapy alone (HR = 0.64, p = 0.0145)
Galinpepimut-SPhase 3VaccineWT1 (Wilms Tumor-1 protein)Weak signal
NCT01266083: Overall Survival (3 years): Galinpepimut-S + Montanide + GM-CSF 47%
LisaftoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MesutoclaxPhase 3Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
MocravimodPhase 3Small moleculeSphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)not yet gradedNo reviewed efficacy summary in this indication
RuserontinibPhase 3Small moleculeFLT3 / EGFR / ABL (also Fyn, Hck, Lck, Lyn, Ret, Yes)Partial signalNo reviewed efficacy summary in this indication
XY0206Phase 3Small moleculeFLT3not yet gradedNo reviewed efficacy summary in this indication
AnnamycinPhase 2/3Small moleculeTopoisomerase II (TOP2)not yet gradedNo reviewed efficacy summary in this indication
BL-M11D1Phase 2/3Antibody–drug conjugateCD33not yet gradedNo reviewed efficacy summary in this indication
Pivekimab Sunirine (Decnupaz)Phase 2/3Antibody–drug conjugateCD123not yet gradedNo reviewed efficacy summary in this indication
CusatuzumabPhase 2Monoclonal antibodyCD70Weak signal
NCT03030612: Objective response in 19/38 patients (8/26 in the phase II portion); complete remission in 14/38
Lintuzumab-Ac225Phase 2RadiopharmaceuticalCD33Weak signalNo reviewed efficacy summary in this indication
PegargiminasePhase 2Protein / enzyme therapeuticArginine-depleting pegylated arginine deiminaseWeak signal
NCT01910012: Among 21 evaluable patients (of 43 enrolled): complete response 2/21 (9.5%), stable disease 7/21 (33.3%), disease control rate 42.9%; CR duration 7.5 and 8.8 months
PrexigebersenPhase 2RNA / oligonucleotideGRB2 (growth factor receptor-bound protein 2) mRNAWeak signalFeatured results are safety only in this race
RomaciclibPhase 2Small moleculeCDK8 / CDK19Weak signal
NCT04021368: RVU120 (CDK8/19 inhibitor) phase 1 dose escalation, AML/HR-MDS (protocol CLI120-001 = NCT04021368): no DLTs, SAEs unrelated to drug; among the first 5 patients treated, 1 CR and 1 erythroid response
Sonrotoclax (Beqalzi)Phase 2Small moleculeBCL-2not yet gradedNo reviewed efficacy summary in this indication
TagraxofuspPhase 2Protein / enzyme therapeuticCD123Weak signalNo reviewed efficacy summary in this indication
VididencelPhase 2VaccineAllogeneic dendritic cell vaccineWeak signal
NCT03697707: MRD response in 7/20 (35%) patients (5/20 converted MRD-negative, 2/20 with >=10-fold MRD reduction). Long-term follow-up (ASH 2025, median 55 months): 13 of 20 patients alive, 8 past 5-year follow-up, estimated 5-year overall survival 63% (sponsor-reported).
AB8939Phase 1/2Small moleculeTubulinnot yet gradedNo reviewed efficacy summary in this indication
ABD-3001Phase 1/2Small moleculeALDH (aldehyde dehydrogenase family, including ALDH1A1/ALDH3A1)not yet gradedNo reviewed efficacy summary in this indication
AlrizomadlinPhase 1/2Small moleculeMDM2Weak signalNo reviewed efficacy summary in this indication
ARD103Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
AZD3632Phase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BexmarilimabPhase 1/2Monoclonal antibodyClever-1not yet gradedNo reviewed efficacy summary in this indication
BG1805Phase 1/2Cell therapyCLL-1 (CLEC12A)not yet gradedNo reviewed efficacy summary in this indication
BSB-1001Phase 1/2Cell therapyHA-1 (minor histocompatibility antigen)not yet gradedNo reviewed efficacy summary in this indication
CART84Phase 1/2Cell therapyCD84not yet gradedNo reviewed efficacy summary in this indication
CCTx-001Phase 1/2Cell therapyIL-1RAPnot yet gradedNo reviewed efficacy summary in this indication
CD123 Targeted CAR-NK CellsPhase 1/2Cell therapyCD123Weak signalNo reviewed efficacy summary in this indication
CD123 / CD33 CARTPhase 1/2Cell therapyCD123 / CD33not yet gradedNo reviewed efficacy summary in this indication
CLN-049Phase 1/2Multispecific antibodyFLT3, CD3not yet gradedNo reviewed efficacy summary in this indication
Debio 1562MPhase 1/2Antibody–drug conjugateCD37not yet gradedNo reviewed efficacy summary in this indication
EmavusertibPhase 1/2Small moleculeIRAK4not yet gradedNo reviewed efficacy summary in this indication
EnzomenibPhase 1/2Small moleculeMenin-KMT2A protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
LigufalimabPhase 1/2Monoclonal antibodyCD47not yet gradedNo reviewed efficacy summary in this indication
MobinitinibPhase 1/2Small moleculeFLT3 / Aurora kinase A and Bnot yet gradedNo reviewed efficacy summary in this indication
MRX-2843Phase 1/2Small moleculeFlt3/MerTKWeak signalNo reviewed efficacy summary in this indication
OcifisertibPhase 1/2Small moleculePLK4 (Polo-like kinase 4)Weak signalFeatured results are safety only in this race
OlverembatinibPhase 1/2Small moleculeBCR-ABL (also AKT, c-Kit, ERK)not yet gradedNo reviewed efficacy summary in this indication
OrcaGraft (Orca-Q)Phase 1/2Cell therapyTreg-enriched allogeneic haematopoietic stem cell graftnot yet gradedNo reviewed efficacy summary in this indication
Anti-CD33 CAR T-CellsPhase 1Cell therapyCD33Weak signalNo reviewed efficacy summary in this indication
PRGN-3006Phase 1Cell therapyCD33Weak signal
NCT03927261: PRGN-3006 (NCT03927261): no dose-limiting toxicities (DLTs) observed.

Large race: only the 64 furthest-along competitors are listed; 66 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(14 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Gemtuzumab Ozogamicin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (1)
December 2026 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2026-12-31 · NCT03737955 · CT.gov ↗
What to watch
2027 (7)
February 2027 (1)
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2027-02 · NCT05183035 · CT.gov ↗
What to watch
April 2027 (2)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04 · NCT05558124 · CT.gov ↗
What to watch
Phase 1/2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-04 · NCT04385290 · CT.gov ↗
What to watch
June 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-06-30 · NCT04050280 · CT.gov ↗
What to watch
November 2027 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-11-25 · NCT06917911 · CT.gov ↗
What to watch
December 2027 (2)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-18 · NCT01409161 · CT.gov ↗
What to watch
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2027-12-31 · NCT03589729 · CT.gov ↗
What to watch
2028 (3)
July 2028 (1)
Phase 2Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2028-07-10 · NCT05199051 · CT.gov ↗
What to watch
October 2028 (1)
Phase 2Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-10-11 · NCT00801489 · CT.gov ↗
What to watch
December 2028 (1)
Phase 1Acute Myeloid LeukemiaRecruiting
Est. primary completion 2028-12-31 · NCT06448013 · CT.gov ↗
What to watch
2029 (2)
January 2029 (1)
Phase 1Acute Myeloid LeukemiaNot yet recruiting
Est. primary completion 2029-01 · NCT05662904 · CT.gov ↗
What to watch
June 2029 (1)
Phase 3Acute Myeloid LeukemiaRecruiting
Est. primary completion 2029-06-30 · NCT04293562 · CT.gov ↗
What to watch
2031 (1)
December 2031 (1)
Phase 3Acute Myeloid LeukemiaActive not recruiting
Est. primary completion 2031-12 · NCT02724163 · CT.gov ↗
What to watch

See the full readout calendar ↗